Amgen Inc. (NASDAQ:AMGN) Shares Purchased by Allen Capital Group LLC

Allen Capital Group LLC boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 14.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,565 shares of the medical research company’s stock after buying an additional 199 shares during the period. Allen Capital Group LLC’s holdings in Amgen were worth $408,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of AMGN. Capital Performance Advisors LLP purchased a new stake in shares of Amgen during the third quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new stake in shares of Amgen during the third quarter worth approximately $29,000. Matrix Trust Co purchased a new stake in shares of Amgen during the third quarter worth approximately $36,000. Livelsberger Financial Advisory purchased a new position in Amgen in the third quarter worth $56,000. Finally, Icon Wealth Advisors LLC raised its position in Amgen by 3,955.0% in the third quarter. Icon Wealth Advisors LLC now owns 174,040 shares of the medical research company’s stock worth $56,000 after acquiring an additional 169,748 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $281.68 on Thursday. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm’s 50-day simple moving average is $271.48 and its 200 day simple moving average is $305.15. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. The stock has a market cap of $151.41 billion, a price-to-earnings ratio of 36.07, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same period in the previous year, the business earned $4.96 EPS. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. As a group, research analysts anticipate that Amgen Inc. will post 19.56 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.38%. Amgen’s payout ratio is currently 115.24%.

Analyst Ratings Changes

AMGN has been the subject of a number of research analyst reports. William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Redburn Partners reduced their price objective on Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Piper Sandler Companies reaffirmed an “overweight” rating and issued a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Barclays raised their target price on Amgen from $300.00 to $315.00 and gave the company an “equal weight” rating in a report on Monday, October 7th. Finally, Piper Sandler dropped their price objective on Amgen from $344.00 to $310.00 and set an “overweight” rating on the stock in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Amgen presently has an average rating of “Hold” and a consensus price target of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.